Supplementary Figure 4: Granulocytic specific Spop deletion does not promote neutrophilia.
a, Immunoblot analysis of Spop protein levels of bone marrow cKit+ cells of wild type, SpopΔ/ΔMxCre and SpopΔ/ΔCreERT2 mice after Poly(I:C) or Tamoxifen treatment. b, Percentage of myeloid (CD11b+Ly6G+) cells in the peripheral blood of (CD11b+Ly6G+) cells in the peripheral blood of Spop KO and control hematopoietic chimeras on the indicated times after Tamoxifen treatment. Data represent mean±s.d. and dots represent different mice. Statistical analysis: unpaired t-test (two-tailed) c, Representative flow cytometry analysis plots of the proportion of myeloid (CD11b+Ly6G+) cells in the peripheral blood of Spop KO and control hematopoietic chimeras on d15 after a sub-lethal LPS injection. d, Representative flow cytometry analysis plots of the proportion of myeloid (CD11b+Ly6G+) cells in the peripheral blood of Spop KO (and control hematopoietic chimeric mice on the indicated days after intranasal influenza inoculation. e, Spop mRNA relative expression levels in the indicated sorted bone marrow cells. Data represent mean±s.d. (n=3 mice per genotype). The results were first standardized for Gapdh expression levels and then each SpopΔ/Δ sample was expressed as a fraction of the expression detected in the correlated control population from the control littermate. g, Percentage of myeloid (CD11b+Ly6G+) cells in the peripheral blood of the indicated mice on d10 following pIpC-challenge (n=5 per genotype). Data represent mean±s.d. and dots represent different mice. Statistical analysis: unpaired t-test (two-tailed). a-f, Data representative of 3 independent experiments.
